The finalists are in for the 10th annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical and medical device industries’ most influential innovators.
Breaking New Grounds in Bone Graft Technology
According to the U.S. Census Bureau, every year more than 1.6 million bonegrafting procedures are performed in the U.S. alone, and in each case, surgeons are faced with the critical decision of choosing an appropriate bone graft technology.
Cerapedics Announces First Patients Enrolled in IDE Clinical Trial of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion Surgery
Cerapedics, a privately-held orthobiologics company, today announced that the first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L Peptide Enhanced Bone Graft in transforaminal lumbar interbody fusion (TLIF) surgery.
Cerapedics Announces Closing of $22 Million Financing
Cerapedics, a privately-held orthobiologics company, today announced that the company completed a $22 million financing led by KCK Group, a family investment fund that focuses on innovative medical technologies that meet significant clinical needs.
Cerapedics Receives 2018 MedTech Breakthrough Award for Best New Surgical Technology Solution
Company recognized for i‑FACTOR™ Peptide Enhanced Bone Graft based on proprietary biomimetic small peptide technology
MedTech Breakthrough Announces Winners of the 2018 MedTech Breakthrough Awards Program
Cerapedics Wins MedTech Breakthrough Award! Best New Technology Solution – Surgical
Cerapedics Announces Results From IVANOS Study of i-FACTOR Peptide Enhanced Bone Graft
Cerapedics, a privately-held orthobiologics company, announced results from the IVANOS study evaluating i-FACTOR Peptide Enhanced Bone Graft in lumbar posterolateral spine surgery.
Cerapedics Receives FDA IDE Approval to Initiate Study of P-15L Bone Graft for Transforaminal Lumbar Interbody Fusion Surgery
Cerapedics, a privately-held orthobiologics company, today announced the company received approval from the U.S. Food and Drug Administration (FDA) to initiate an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of P-15L Peptide Enhanced Bone Graft compared to autograft in transforaminal lumbar interbody fusion (TLIF) surgery for degenerative disk disease.
Cerapedics Announces i-FACTOR™ Peptide Enhanced Bone Graft Adopted by More than 150 Leading U.S. Hospitals
Cerapedics, a privately-held orthobiologics company, today announced that more than 150 leading U.S. hospitals have now adopted use of i-FACTOR™ Peptide Enhanced Bone Graft.
Cerapedics Announces Appointment of Doug Kohrs to Board of Directors and Names Antony Koblish Board Chair
Cerapedics, a privately-held orthobiologics company, today announced the appointment of Doug Kohrs to the company’s board of directors and the appointment of Antony Koblish as board chair.